WEBINAR VIDEO | Life Sciences Session #9: Hot topics in healthcare tendering

WEBINAR VIDEO | Life Sciences Session #9: Hot topics in healthcare tendering
November 28, 2022

Please join us on 28 November 2022 from 13:30 to 14:30 for our ninth online Life Sciences Session, where Caroline De Mulder and Kirian Claeyé will discuss the latest evolutions in the field of healthcare public procurement and will answer questions such as:

  • Is a supplier entitled to indexation of its prices due to the current economic crisis?
  • What’s the impact of the new article 71bis of the law of 14 July 1994 concerning the compulsory insurance for medical care and benefits (in Dutch: “ZIV-wet”, in French: “loi AMI”) on tendering for biologicals and biosimilars?
  • In which context can suppliers offer benefits to the contracting hospitals?

Contact

  • Kirian Claeyé

    Counsel

  • Caroline De Mulder

    Counsel

Recommended articles

January 16, 2023

When are IP holders liable for enforcing a later invalidated IP right?

At this IP Update, our IP specialists, Christophe Ronse and Kirian Claeyé, will discuss under what circumstances IP holders may be held liable for enforcing a later invalidated IP right.

Read on
January 05, 2023

EU harmonizes THC limits in hemp seed (food) as from 1 January 2023

Hemp seeds have been eaten in the EU for a long time. The seeds may contain trace amounts of tetrahydrocannabinol (THC) because this cannabinoid is a natural constituent of the cannabis plant from which the seeds originate. The EU regulator has decided to harmonize the maximum levels for THC in hemp seeds throughout the Union within the food contaminants framework.

Read on
December 21, 2022

WEBINAR VIDEO | What do the CJEU’s decisions on parallel trade of medicines mean for your company?

At this additional Christmas edition, the IP specialists in our Life Sciences team discuss the CJEU’s latest decisions on the parallel trade of medicines, and what these decisions mean in practice for your company. On 17 November 2022, the CJEU delivered essentially two decisions on the parallel trade of medicines. The first concerned the rebranding […]

Read on